Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 189 entries
View as:

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

Phase: N/A Priority: Normal
NCT ID: NCT03056690 Org: User:
Start: 03/20/17 End: 02/27/18 Due: 02/27/19

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT04476849 Org: User:
Start: 08/10/20 End: 03/11/22 Due: 03/11/23

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Phase: N/A Priority: Normal
NCT ID: NCT02799745 Org: User:
Start: 06/09/16 End: 08/28/20 Due: 08/28/21

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03964038 Org: User:
Start: 05/21/19 End: 07/16/19 Due: 07/16/20

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT04079296 Org: User:
Start: 09/19/19 End: 04/21/23 Due: 04/21/24

A Study of ASP1012 in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06171178 Org: User:
Start: 05/15/24 End: 06/30/29 Due: 06/30/30

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01606982 Org: User:
Start: - End: - Due: -

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Phase: N/A Priority: Normal
NCT ID: NCT02091999 Org: User:
Start: 05/14/14 End: 12/07/22 Due: 12/07/23

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01918995 Org: User:
Start: 05/31/13 End: 08/31/13 Due: 08/31/14

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Phase: N/A Priority: Normal
NCT ID: NCT01877655 Org: User:
Start: 09/11/13 End: 03/01/22 Due: 03/01/23

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Phase: N/A Priority: Normal
NCT ID: NCT01977651 Org: User:
Start: 09/25/13 End: 01/11/19 Due: 01/11/20

A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02528643 Org: User:
Start: 11/09/15 End: 02/09/21 Due: 02/09/22

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02441517 Org: User:
Start: 10/28/15 End: 03/15/17 Due: 03/15/18

Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT01678287 Org: User:
Start: 11/30/07 End: 01/31/08 Due: 01/31/09

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02610062 Org: User:
Start: 03/29/16 End: 11/21/17 Due: 11/21/18

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02421939 Org: User:
Start: 10/20/15 End: 02/25/25 Due: 02/25/26

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

Phase: N/A Priority: Normal
NCT ID: NCT01998646 Org: User:
Start: 08/31/10 End: 07/31/12 Due: 07/31/13

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03260322 Org: User:
Start: 09/08/17 End: 05/10/22 Due: 05/10/23

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07005154 Org: User:
Start: 06/30/25 End: 05/31/32 Due: 05/31/33

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01963052 Org: User:
Start: 11/14/13 End: 07/08/19 Due: 07/08/20

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02111317 Org: User:
Start: 10/31/13 End: 11/30/13 Due: 11/30/14

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

Phase: N/A Priority: Normal
NCT ID: NCT01660477 Org: User:
Start: 06/30/12 End: 10/31/12 Due: 10/31/13

Registry of Patients Treated With Systemic Mold-Active Triazoles

Phase: N/A Priority: Normal
NCT ID: NCT03066011 Org: User:
Start: 03/16/17 End: 04/24/20 Due: 04/24/21

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01630083 Org: User:
Start: 07/19/12 End: 01/31/19 Due: 01/31/20

Early Access Program for Zolbetuximab

Phase: N/A Priority: Normal
NCT ID: NCT06048081 Org: User:
Start: - End: - Due: -